Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

50.35 -0.87 (-1.70%)

Streaming Delayed Price Updated: 1:14 PM EST, Dec 16, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

34 35 Next >

The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation ↗

February 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Roche Expects Slower FY22 Sales Growth On Lower Demand For COVID-19 Tests ↗

February 03, 2022

Roche Holdings AG's (OTC: RHHBY) FY21 sales increased 8% Y/Y (9% on a constant currency basis) to CH

Via Benzinga

Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues ↗

February 02, 2022

Novartis AG (NYSE: NVS) reported a Q4 net income of $16.31 billion, up from $2.1 billion the previous year,

Via Benzinga

World Markets News for Tuesday ↗

February 01, 2022

Exxon is splitting into 3 with its new restructuring move: upstream; chemicals; and low-carbon.

Via Talk Markets

Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab ↗

February 01, 2022

Biogen Inc (NASDAQ: BIIB) has

Via Benzinga

The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News ↗

January 31, 2022

The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower.

Via Benzinga

FDA Approves First Injectable Eye Medicine For Vision Loss Disorder - Genentech's Vabysmo ↗

January 31, 2022

The FDA has approved Genentech's, a unit of

Via Benzinga

FDA Approves Genentech’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss

January 28, 2022

From Genentech

Via Business Wire

Drug Troubles ↗

January 28, 2022

The drug sector has both good news and bad.

Via Talk Markets

Genentech's Evrysdi Application Under FDA Priority Review For Use In Babies Below 2 Months ↗

January 25, 2022

The FDA has granted priority review for Genentech's, a unit of Roche Holdings AG (OTC: RHHBY) supplemental marketing application for Evrysdi (...

Via Benzinga

These OTC Securities Had the Most Trading Activity in December ↗

January 25, 2022

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be i...

Via Benzinga

Genentech’s Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-Symptomatic Babies Under 2 Months of Age With Spinal Muscular Atrophy (SMA)

January 25, 2022

From Genentech

Via Business Wire

The Lancet Publishes Studies Showing Genentech’s Faricimab Improved and Maintained Vision in Two Leading Causes of Vision Loss, Extending Time Between Treatments up to Four Months

January 24, 2022

From Genentech

Via Business Wire

The Week Ahead In Biotech (Jan. 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, & More ↗

January 23, 2022

Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that...

Via Talk Markets

Chopped Stocks ↗

January 18, 2022

The day's theme is sell tech and buy banks.

Via Talk Markets

MLK Day Global News ↗

January 17, 2022

In Q4 China's GDP growth rate halved to 4%.

Via Talk Markets

More Serious Matters ↗

January 14, 2022

Wall Street fell on new worries about inflation and a drop in retail sales levels.

Via Talk Markets

Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019

January 14, 2022

FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 14, 2022 – USA News Group – Cancer cases are on the rise, according to a new study comparing the number of cancer...

Via FinancialNewsMedia

Topics Death

Interest Rate Hikes And Stocks ↗

January 12, 2022

Abnormal flooding in northwest Brazil has blocked iron ore mining which resulted in a jump in the price of ore.

Via Talk Markets

CMS Proposes Coverage Of Biogen's Alzheimer's Drug, With Conditions Apply ↗

January 12, 2022

The Centers for Medicare & Medicaid Services (CMS) released a proposed national coverage determination for Medicare to cover drugs that target amyloid for mild...

Via Benzinga

Happy New Year - Sunday Edition ↗

January 02, 2022

Starting a new year - we look at tech, pharma and mining stocks and their goings-on.

Via Talk Markets

Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates ↗

December 31, 2021

Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were...

Via Benzinga

Healthcare Stocks Are Winners And Provide Diversification To Your Portfolio ↗

December 30, 2021

As we have written their year many times speculative small cap biotechs have not done well in 2021 since they peaked in February.

Via Talk Markets

Boxing Day Finance ↗

December 27, 2021

Today we saw the Dow Jones move up over 36,000.

Via Talk Markets

Free COVID Tests: What Stocks Will Benefit? ↗

December 23, 2021

The government hasn’t announced yet what company or companies it will be buying from, but there are several businesses involved in producing these kits.

Via Talk Markets

Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot ↗

December 22, 2021

The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022.

Via Talk Markets

Dreaming Of A Red Christmas ↗

December 20, 2021

The stock market is reacting with lots of selling to the weekend's news.

Via Talk Markets

Lineage, Genentech Ink Cell Therapy Licensing Pact For Ocular Diseases ↗

December 20, 2021

Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into an exclusive worldwide collaboration and license agreement with Roche Holdings AG's (OTC: RHHBY)...

Via Benzinga

Raising Rates ↗

December 16, 2021

The Bank of England raised its interest rate to 0.25%, setting a pattern for other countries.

Via Talk Markets

These OTC Securities Had the Most Trading Activity in November ↗

December 16, 2021

Photo by Markus Winkler on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...

Via Benzinga

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

All News about Roche Holding AG Basel American Depositary Shares

Starting at $3.75/week.

Subscribe Today